Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

As it advances its nonopioid analgesic ATX-101 breakthrough therapy through a phase IIb registration trial, Allay Therapeutics secured $57.5 million in a series D round, which included an investment ...

Immunoprecise Antibodies Ltd. has discovered a highly conserved epitope across all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) using its proprietary Lensai platform powered by its ...

Solvonis Therapeutics plc has completed synthesis of development candidates for its SVN-SDN-014 program, a novel series of serotonin, dopamine and noradrenaline modulators.

Mindimmune Therapeutics Inc. has been awarded a grant by Rhode Island Life Science Hub to accelerate preclinical development work on MITI-101 for the treatment of mild to moderate Alzheimer’s disease.

The EMA’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending European orphan drug designation for Hemispherian AS’s GLIX-1 for the treatment of glioma.

Astrazeneca AB has divulged 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of alcoholic liver disease, liver fibrosis, cirrhosis, hepatic ...